title: Quantitative fluorescence cytometric measurement of estrogen and progesterone receptors: correlation with the hormone binding assay.
abstract: We describe, here, a rapid flow cytometry technique for the detection and quantification of estrogen (ER) and progesterone (PgR) receptors in several human cell lines and in clinical samples obtained from breast cancer tumors. ER and PgR quantitation can be very useful in patients with breast cancer as their role in diagnosis and prognosis is well established. However ligand binding assays and immunohistochemical assays are difficult to measure heterogeneity in individual cells. On the other hand, flow cytometry is a convenient tool for quantification in individual cells. Flow cytometric results with breast cancer cell lines and clinical samples were compared to those obtained by quantitative biochemical ER and PgR performed by the standard dextran-coated charcoal biochemical assay. The latter assay is affected by the level of endogenous steroids. This is also the case in the routine measurement of ER/PgR in patient's tumor cells whereby estradiol molecules in patient's serum produced negative or low values in the biochemical assay. The mAbs used in our flow cytometric method bind to their specific ER or PgR independently of whether they are preoccupied by their ligands and they produce reliable results. With the use of beads calibrated in MESF (Molecules of Equivalent Soluble Fluorochrome) units, the ER and PgR can be measured on a per cell basis. The flow cytometric method showed a strong correlation with biochemical receptor assessments of either ER alpha (ER alphaDCC, r = 0.918, p = 0.073) or PgR (PgRDCC, r = 0.75, p = 0.001). This study demonstrates that ER alpha and PgR can be detected by flow cytometry on a per cell basis in intact cells, and can be quantitated reliably in terms of MESF without the limitations of competition with serum's estradiol molecules.
authors.affiliation: Department of Immunology, Saint Savas Cancer Hospital, Athens, Greece. cacenter@otenet.gr
authors.forename: Angelos D
authors.initials: AD
authors.lastname: Gritzapis
authors.forename: Constantin N
authors.initials: CN
authors.lastname: Baxevanis
authors.forename: Ioannis
authors.initials: I
authors.lastname: Missitzis
authors.forename: Efrosine S
authors.initials: ES
authors.lastname: Katsanou
authors.forename: Michael N
authors.initials: MN
authors.lastname: Alexis
authors.forename: Julia
authors.initials: J
authors.lastname: Yotis
authors.forename: Michael
authors.initials: M
authors.lastname: Papamichail
mesh_terms: D001943:Breast Neoplasms / Q000737:chemistry* / Q000175:diagnosis; D005260:Female; D005434:Flow Cytometry / Q000379:methods*; D019084:Fluorescent Antibody Technique, Indirect; D006801:Humans; D007150:Immunohistochemistry; D008856:Microscopy, Fluorescence; D011379:Prognosis; D011960:Receptors, Estrogen / Q000032:analysis*; D011980:Receptors, Progesterone / Q000032:analysis*; D014407:Tumor Cells, Cultured
chemical_list: D011960:Receptors, Estrogen; D011980:Receptors, Progesterone